Alnylam's makes progress with RNAi program

RNAi trailblazer Alnylam has published a paper in the journal Human Molecular Genetics that details RNAi's ability to silence a gene implicated in early onset torsion dystonia. Dystonia is a neurological movement disorder in which sustained muscle contractions cause twisting and repetitive movements or abnormal posture. According to Dinah Sah, Ph.D., Senior Director of Research at Alnylam, the data demonstrates RNAi therapeutics can discriminate between a disease target of interest and a closely related gene, which could help treat genetic disorders.

"We are encouraged by these results, as well as results we have seen to date with our other neurological RNAi therapeutic programs, such as Huntington's disease, Parkinson's disease, and others," added Sah.

- read the release

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

Takeda’s experimental TAK-620 (maribavir) has hit its main phase 3 goal in helping transplant patients with refractory/resistant cytomegalovirus.

The Chinese vaccine developer committed to starting the late-phase study this month after reviewing data on 150 participants in a phase 1 trial.

Antibody levels stayed elevated in the 90 days after people received the second dose of Moderna’s COVID-19 vaccine.